


# Supplementary Materials: Mitochondrial Respiration in *KRAS* and *BRAF* Mutated Colorectal Tumors and Polyps

Egle Rebane-Klemm, Laura Truu, Leenu Reinsalu, Marju Puurand, Igor Shevchuk, Vladimir Chekulayev, Natalja Timohhina, Kersti Tepp, Jelena Bogovskaja, Vladimir Afanasjev, Külliki Suurmaa, Vahur Valvere and Tuuli Kaambre



**Figure S1.** Regulation of mitochondrial respiration in *KRAS*+, *BRAF*+ and wild-type tumors and controls. (A) Comparative analysis of maximal respiratory rate ( $V_{max}$ ) and (B) the apparent Michaelis-Menten constant ( $K_m(ADP)$ ) values for ADP. *KRAS*+—*KRAS* mutated; *BRAF*+—*BRAF* mutated; WT—wild type; CRC—colorectal cancer; P—polyps; Control—control tissue. \*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ .

**Table S1.** The maximal ADP-activated respiration rates ( $V_{max}$ ) comparison by molecular groups. Respiration rates are given in  $\text{nmol O}_2/(\text{min} \times \text{mg dry weight})$  *KRAS*+—*KRAS* mutated; *BRAF*+—*BRAF* mutated; WT—wild-type; CRC—colorectal cancer; P—polyps; Control—control tissue.

$V_{max}$ Comparison by Molecular Groups				
Group (n)	$V_{max}$ value, $\text{nmol O}_2/(\text{min} \times \text{mg dry weight})$	Group (n)	$V_{max}$ value, $\text{nmol O}_2/(\text{min} \times \text{mg dry weight})$	p value
<i>KRAS</i> + CRC (n = 19)	$1.93 \pm 0.16$	<i>BRAF</i> + CRC (n = 7)	$1.22 \pm 0.30$	0.037
<i>KRAS</i> + CRC (n = 19)	$1.93 \pm 0.16$	WT CRC (n = 16)	$2.67 \pm 0.27$	0.021
<i>BRAF</i> + CRC (n = 7)	$1.22 \pm 0.30$	WT CRC (n = 16)	$2.67 \pm 0.27$	0.004
<i>KRAS</i> + CRC (n = 19)	$1.93 \pm 0.16$	<i>KRAS</i> + P (n = 7)	$2.19 \pm 0.19$	0.383
<i>BRAF</i> + CRC (n = 7)	$1.22 \pm 0.30$	<i>BRAF</i> + P (n = 2)	$1.41 \pm 0.27$	0.755
WT CRC (n = 16)	$2.67 \pm 0.27$	WT P (n = 13)	$1.95 \pm 0.28$	0.079
<i>KRAS</i> + CRC (n = 19)	$1.93 \pm 0.16$	Control (n = 18)	$1.08 \pm 0.12$	<0.001
<i>BRAF</i> + CRC (n = 7)	$1.22 \pm 0.30$	Control (n = 18)	$1.08 \pm 0.12$	0.601
WT CRC (n = 16)	$2.67 \pm 0.27$	Control (n = 18)	$1.08 \pm 0.12$	<0.001
<i>KRAS</i> + P (n = 7)	$2.19 \pm 0.19$	Control (n = 18)	$1.08 \pm 0.12$	<0.001
<i>BRAF</i> + P (n = 2)	$1.41 \pm 0.27$	Control (n = 18)	$1.08 \pm 0.12$	0.373
WT P (n = 13)	$1.95 \pm 0.28$	Control (n = 18)	$1.08 \pm 0.12$	0.004

**Table S2.**  $K_m$  comparison by molecular groups. *KRAS*+—*KRAS* mutated; *BRAF*+—*BRAF* mutated; WT—wild type; CRC—colorectal cancer; P—polyps; Control—control tissue.

<b><math>K_m</math> Comparison by Molecular Groups</b>				
<b>Group (<i>n</i>)</b>	<b><math>K_m</math> value, (<math>\mu</math>M)</b>	<b>Group (<i>n</i>)</b>	<b><math>K_m</math> value, (<math>\mu</math>M)</b>	<b><i>p</i> value</b>
KRAS+ CRC ( <i>n</i> = 18)	116.60 ± 13.86	BRAF+ CRC ( <i>n</i> = 7)	86.02 ± 12.15	0.209
KRAS+ CRC ( <i>n</i> = 18)	116.60 ± 13.86	WT CRC ( <i>n</i> = 14)	106.55 ± 19.72	0.671
BRAF+ CRC ( <i>n</i> = 7)	86.02 ± 12.15	WT CRC ( <i>n</i> = 14)	106.55 ± 19.72	0.494
KRAS+ CRC ( <i>n</i> = 18)	116.60 ± 13.86	KRAS+ P ( <i>n</i> = 7)	55.33 ± 7.40	0.014
BRAF+ CRC ( <i>n</i> = 7)	86.02 ± 12.15	BRAF+ P ( <i>n</i> = 2)	52.45 ± 4.67	0.204
WT CRC ( <i>n</i> = 14)	106.55 ± 19.72	WT P ( <i>n</i> = 13)	60.07 ± 6.32	0.039
KRAS+ CRC ( <i>n</i> = 18)	116.60 ± 13.86	Control ( <i>n</i> = 18)	114.43 ± 10.23	0.901
BRAF+ CRC ( <i>n</i> = 7)	86.02 ± 12.15	Control ( <i>n</i> = 18)	114.43 ± 10.23	0.131
WT CRC ( <i>n</i> = 14)	106.55 ± 19.72	Control ( <i>n</i> = 18)	114.43 ± 10.23	0.708
KRAS+ P ( <i>n</i> = 7)	55.33 ± 7.40	Control ( <i>n</i> = 18)	114.43 ± 10.23	0.002
BRAF+ P ( <i>n</i> = 2)	52.45 ± 4.67	Control ( <i>n</i> = 18)	114.43 ± 10.23	0.064
WT P ( <i>n</i> = 13)	60.07 ± 6.32	Control ( <i>n</i> = 18)	114.43 ± 10.23	<0.001



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).